Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?

Area of Science:

• Biochemistry
• Neuroscience
• Pharmacology

Background:

• Targeted protein degradation (TPD) is a growing therapeutic strategy, with proteolysis-targeting chimeras (PROTACs) in clinical trials and molecular glues approved for blood cancers.
• Current TPD applications primarily focus on oncology, leaving potential in other areas like neurodegenerative diseases unexplored.
• Degrading challenging targets, such as protein aggregates in neurodegenerative conditions, presents a novel therapeutic avenue.

Purpose of the Study:

• To review the potential of TPD strategies for neurodegenerative disease targets.
• To discuss the application of PROTAC and molecular glue formats for central nervous system (CNS) targets.
• To explore opportunities for novel CNS E3 ligases in TPD.

Main Methods:

• Literature review of TPD modalities (PROTACs, molecular glues).
• Focus on applications for neurodegenerative disease targets.
• Discussion of CNS-specific challenges and opportunities.

Main Results:

• TPD offers a promising approach for targets intractable by traditional inhibition, including those in neurodegenerative diseases.
• PROTACs and molecular glues show potential for CNS applications.
• Identification of novel CNS E3 ligases is a key area for future development.

Conclusions:

• TPD modalities represent a significant therapeutic prospect for neurodegenerative diseases.
• Overcoming challenges in molecular design, drug delivery, and blood-brain barrier penetration is crucial for CNS TPD success.
• Further research into CNS E3 ligases and degrader optimization is warranted.